

References

I-14

1. Hizentra®, Immune Globulin Subcutaneous (Human)[package insert]. Kankakee, IL: CSL Behring LLC; 03/2010, Revised 09/2013.
2. Gamunex®-C [package insert]. Research Triangle Park, NC: Grifols Therapeutics Inc; 2003, Revised 09/2013.
3. Octagam [package insert]. Hoboken, NJ: Octapharma USA INC; 2004, Revised 09/2014.
4. GAMMAGUARD LIQUID [package insert]. Westlake Village, CA: Baxter International Inc; 2005, Revised 09/2013.
5. Vivaglobin® [package insert]. Kankakee, IL: CSL Behring LLC; 2006, Revised 04/2010.
6. Cytogam® [package insert]. Kankakee, IL: CSL Behring LLC; 2007, Revised 08/2012.
7. Privigen® [package insert]. Kankakee, IL: CSL Behring LLC; 2007, Revised 11/2013.
8. Gammaplex® [package insert]. Raleigh, NC: BPL Inc; 2009, Revised 09/2013.
9. Rhophylac [package insert]. Kankakee, IL: CSL Behring LLC; 2010.
10. Crabol Y, Terrier B, Rozenberg F, et al. Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature. *Clin Infect Dis*. 2013;56(7):968-977.
11. Ohlsson A, Lacy JB. Intravenous immunoglobulin for preventing infection in preterm and/or low birth weight infants. *Cochrane Database Syst Rev*.2013;7:CD000361.Jordan JA, PhD. Treatment and prevention of parvovirus B19 infection. UpToDate. Literature review current through: March 2014.
12. Schrier SL, MD. Treatment of autoimmune hemolytic anemia: Warm agglutinins. UpToDate. Literature review current through: March 2014.
13. Lingman-Framme J, Fasth A. Subcutaneous immunoglobulin for primary and secondary immunodeficiencies: an evidence-based review. *Drugs*. 2013;73(12):1307-19.
14. Souayah N, Hasan A, Khan H, et al. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders. *J Clin Neuromuscul Dis*. 2011;12.
15. Ayer G, Souayah N. Efficacy and safety of home infusion of intravenous immunoglobulin in multifocal motor neuropathy: A longitudinal study. *J Amer Academy Neurol*. 2014;10(82). Sup P7.111.
16. Abolhassani H, Sadaghiani MS, Aghamohammadi A, Ochs HD, Rezaei N. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta-analysis. *J Clin Immunol*. 2012;32(6):1180-92
17. American Academy of Allergy Asthma & Immunology (AAAAI). 8 guiding principles for effective use of IVIG for patients with primary immunodeficiency.

18. AxelaCare Health Solutions, LLC in collaboration with Bio Products Laboratory (BPL) are currently recruiting patients for a trial to demonstrate monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammalex® IVIg in the Home Setting.
19. Hasan A. Reducing adverse reactions in home IVIG administration; Large walgreen study shows clinical protocols affect outcomes. *Neuropathy Association*. 2014.
20. HyQvia Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase [FDA package insert]. 2014.
21. Huang YH, Chen HC, Huang KW, et al. Intravenous immunoglobulin for postpolio syndrome: a systematic review and meta-analysis. *BMC Neurol*. 2015;15:39
22. Olyaeemanesh A, Rahmani M, et al. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis. *Med J Islamic Repub of Iran*. 2016;1-11.
23. Brandt-Wouters E, Gerlach O HH, Hupperts RMM. The effect of postpartum intravenous immunoglobulins on the relapse rate among patients with multiple sclerosis. *Int J Gyn Obs*. 2016;194-196.
24. Williams KA, Swedo SE, Farmer CA, et al. Randomized, Controlled Trial of Intravenous Immunoglobulin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections. *J Am Acad Child Adolesc Psychiatry*. 2016;55(10):860–867.
25. Patwa HS, Chaudhry V, Katzberg H, Rae-Grant AD, So YT. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorders: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2012;27;78(13):1009-15.
26. Elovaara I, Apostolski S, van Doorn P, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases. *Eur J Neuro*. 2008;893-908.
27. Cuvitru Immune Globulin Subcutaneous (Human), 20% Solution. [FDA package insert]. 2016.
28. American Academy of Allergy Asthma and Immunology. Guidelines for the site of care for administration of IGIV therapy. December 2011.
29. MCG™ Care Guidelines, 21st edition, 2017, Home Infusion Therapy, CMT: CMT-0009(SR).
30. Katzberg H, Rasutis V, Bril V Home iVIG for CIDP: A Focus on Patient Centered Care *Can J Neurol Sci*. 2013;40:384-388.
31. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. *Healthcare*. 2016.